Effect of FXR and PPARγ ligands on liver fibrosis induced by 8-week administration of porcine serum to rats Rats were treated twice a week for 8 weeks with repeated intraperitoneal injections of either saline or porcine serum along with oral administrations of FXR and PPARγ ligands. The body weight was measured immediately before sacrificing. After removal of the liver, it was weighed, and the ratio to whole-body weight was then calculated. Data are mean ± S.E. of indicated number of rats.
Treatment | No. of rats | Final b.wt. | Liver/b.wt. | ALT | ALP | Bilirubin |
|---|---|---|---|---|---|---|
| g | % | U/l | U/dl | mg/dl | ||
| Control | 6 | 376.0 ± 10.5 | 2.60 ± 0.5 | 34.3 ± 4.4 | 22.5 ± 3.6 | 0.1 ± 0.01 |
| PS (8 weeks) | 10 | 354.3 ± 12.3 | 4.1 ± 0.5* | 46.4 ± 5.4 | 29.0 ± 5.2 | 0.3 ± 0.01 |
| PS + 6-ECDCA (1 mg/kg) | 10 | 357.3 ± 9.8 | 3.8 ± 0.3 | 47.4 ± 2.4 | 26.6 ± 2.5 | 0.3 ± 0.01 |
| PS + 6-ECDCA (3 mg/kg) | 10 | 352.4 ± 10.3 | 2.9 ± 0.2 | 41.9 ± 5.3 | 21.8 ± 5.2 | 0.2 ± 0.01 |
| PS + rosiglitazone (1 mg/kg) | 10 | 346.9 ± 11.5 | 4.0 ± 0.3 | 47.6 ± 4.2 | 23.4 ± 3.7 | 0.3 ± 0.06 |
| PS + rosiglitazone (3 mg/kg) | 10 | 358.3 ± 11.8 | 2.81 ± 0.4 | 40.7 ± 5.2 | 25.6 ± 3.1 | 0.3 ± 0.07 |
| PS + 6-ECDCA (1 mg/kg) + rosiglitazione (1 mg/kg) | 10 | 361.4 ± 8.9 | 3.1 ± 0.5 | 40.4 ± 4.2 | 28.9 ± 2.7 | 0.1 ± 0.02 |
|
PS + 6-ECDCA (3 mg/kg) + rosiglitazione (3 mg/kg) |
10 |
369.6 ± 10.8 |
2.7 ±
0.4** |
37.5 ± 3.3 |
22 ± 4.2 |
0.2 ± 0.01 |